Bacterial Factors That Predict Relapse after Tuberculosis Therapy

The New England Journal of Medicine
Roberto ColangeliDMID 01-009/Tuberculosis Trials Consortium Study 22 Teams

Abstract

Approximately 5% of patients with drug-susceptible tuberculosis have a relapse after 6 months of first-line therapy, as do approximately 20% of patients after 4 months of short-course therapy. We postulated that by analyzing pretreatment isolates of Mycobacterium tuberculosis obtained from patients who subsequently had a relapse or were cured, we could determine any correlations between the minimum inhibitory concentration (MIC) of a drug below the standard resistance breakpoint and the relapse risk after treatment. Using data from the Tuberculosis Trials Consortium Study 22 (development cohort), we assessed relapse and cure isolates to determine the MIC values of isoniazid and rifampin that were below the standard resistance breakpoint (0.1 μg per milliliter for isoniazid and 1.0 μg per milliliter for rifampin). We combined this analysis with clinical, radiologic, and laboratory data to generate predictive relapse models, which we validated by analyzing data from the DMID 01-009 study (validation cohort). In the development cohort, the mean (±SD) MIC of isoniazid below the breakpoint was 0.0334±0.0085 μg per milliliter in the relapse group and 0.0286±0.0092 μg per milliliter in the cure group, which represented a higher value ...Continue Reading

Associated Clinical Trials

References

Jan 25, 2000·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S Ramaswamy, J M Musser
May 3, 2003·The Lancet Infectious Diseases·Marie-Laurence LambertPatrick Van der Stuyft
May 20, 2006·American Journal of Respiratory and Critical Care Medicine·Awal KhanC Robert Horsburgh
Aug 25, 2006·The New England Journal of Medicine·Anis RassiMaurício I Scanavacca
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeremy M G TaylorRebecca R Andridge
Jun 23, 2009·American Journal of Respiratory and Critical Care Medicine·John L JohnsonW Henry Boom
Jun 1, 2010·The Lancet Infectious Diseases·David J HorneKaren R Steingart
Sep 3, 2010·Nature Reviews. Gastroenterology & Hepatology·Bahaa E SenousyPeter V Draganov
Mar 19, 2011·BMC Bioinformatics·Xavier RobinMarkus Müller
Mar 25, 2011·European Journal of Epidemiology·Suman KunduA Cecile J W Janssens
Nov 8, 2011·Canadian Respiratory Journal : Journal of the Canadian Thoracic Society·Aylin BabalikDick Menzies
Jul 18, 2012·Antimicrobial Agents and Chemotherapy·Jurriaan E M de SteenwinkelIrma A J M Bakker-Woudenberg
Aug 1, 2013·The Journal of Infectious Diseases·Jotam G PasipanodyaTawanda Gumbo
Oct 9, 2013·Antimicrobial Agents and Chemotherapy·Jongseok LeeMoses L Joloba
Apr 18, 2014·Journal of Clinical Microbiology·F B JamiesonC Mehaffy
May 3, 2014·The New England Journal of Medicine·Suzanne T AndersonBrian Eley
Sep 10, 2014·The New England Journal of Medicine·Stephen H GillespieUNKNOWN REMoxTB Consortium
Oct 23, 2014·The New England Journal of Medicine·Corinne S MerleUNKNOWN OFLOTUB/Gatifloxacin for Tuberculosis Project
Mar 13, 2016·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S M MarksUNKNOWN TB Epidemiologic Studies Consortium

❮ Previous
Next ❯

Citations

Aug 30, 2018·The New England Journal of Medicine·Eric J Rubin
Dec 27, 2018·Environmental Microbiology Reports·Pranay Sinha, Natasha S Hochberg
Jan 10, 2019·The New England Journal of Medicine
Dec 19, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lina Davies ForsmanJudith Bruchfeld
Jul 4, 2019·British Journal of Clinical Pharmacology·Robin J SvenssonUlrika S H Simonsson
Jul 25, 2019·Expert Opinion on Drug Metabolism & Toxicology·Christine Sekaggya-Wiltshire, Kelly E Dooley
May 3, 2019·American Journal of Respiratory and Critical Care Medicine·Michael S NiedermanNeil W Schluger
Aug 16, 2019·PloS One·Samantha Flores-TreviñoRayo Morfín-Otero
Sep 20, 2019·PLoS Pathogens·Jeremy Rock
Sep 7, 2019·Proceedings of the National Academy of Sciences of the United States of America·Hassan SafiDavid Alland
Sep 19, 2019·Molecular Biology and Evolution·Rhastin A D CastroSebastien Gagneux
Feb 16, 2020·The European Respiratory Journal·Camus NimmoMax O'Donnell
Sep 29, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jan-Willem C AlffenaarGiovanni Battista Migliori
Oct 28, 2019·Frontiers in Oncology·Longhai LiYong Mao
Jun 26, 2020·Science Translational Medicine·Sarah M SchraderCarl Nathan
Nov 9, 2018·Clinical Pharmacokinetics·Alper DaskapanJan-Willem C Alffenaar
May 11, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Geetha RamachandranUNKNOWN Cohort for Tuberculosis Research by the Indo-US Partnership (CTRIUMPh) Team
Jun 11, 2020·The New England Journal of Medicine·Mathieu S BolhuisOnno W Akkerman
Aug 25, 2019·International Journal of Molecular Sciences·Antal MartineczPia Abel Zur Wiesch
Apr 2, 2020·Proceedings of the National Academy of Sciences of the United States of America·Ove ØyåsMattia Zampieri
Aug 17, 2020·PLoS Computational Biology·Fabrizio ClarelliPia Abel Zur Wiesch
Nov 4, 2020·Biomarkers in Medicine·Vladyslav NikolayevskyyFrancis Drobniewski
Jun 11, 2020·The New England Journal of Medicine·Francesca ConradieAngela M Crook
Jan 11, 2019·The New England Journal of Medicine·Abdullah AlsultanCharles A Peloquin
Jan 26, 2020·The Journal of Infection·Irina V PeretokinaDanila V Zimenkov
May 28, 2021·European Respiratory Review : an Official Journal of the European Respiratory Society·Irina KontsevayaJan Heyckendorf
Jul 17, 2021·The Journal of Experimental Medicine·Hongwei SuSabine Ehrt
Aug 7, 2021·Frontiers in Digital Health·Allison J Lopatkin, Jason H Yang
Jul 10, 2021·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hyung Woo KimJu Sang Kim
Jul 13, 2021·Antimicrobial Agents and Chemotherapy·Andrew D GewitzUNKNOWN Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.